Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Language
Publication year range
1.
Niger J Clin Pract ; 26(9): 1303-1308, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37794543

ABSTRACT

Background: In early-stage lip cancer, spread to cervical lymph nodes is extremely rare. Elective neck treatment options include suprahyoid or supraomohyoid neck dissection, sentinel lymph node biopsy, or close follow-up. Aim: In this study, our aim was to investigate the effect of elective surgery on survival in patients operated for early-stage lip cancer. Methods: Patients who underwent surgical treatment for lower lip squamous cell carcinoma between 2005 and 2020 were retrospectively analyzed. Age, gender, neck dissection status (yes/no), clinical and pathological T stage of the tumor, grade, and perineural invasion were recorded and 3-year and 5-year overall (OS) and disease-free survival (DFS) rates were estimated. Results: Thirty patients were included: 20 patients had pT1 and 10 patients had pT2 tumors. Neck dissection was performed in 13 patients. The 5-year OS rate was 90.9% and 87.8% with and without dissection, respectively. Neck dissection did not appear to affect OS (P = 0.534) in these patients. The 5-year DFS rate was 96.4% in the overall group, while it was 91.7% and 100% in patients who did or did not undergo neck dissection, respectively (P = 0.756). Discussion: Patients with or without neck dissection did not differ significantly in terms of OS and DFS. Watchful waiting with regular ultrasound imaging of the neck in patients with T1 and T2 lip tumors may be an appropriate therapeutic option.


Subject(s)
Head and Neck Neoplasms , Lip Neoplasms , Humans , Neck Dissection/methods , Lip Neoplasms/surgery , Lip Neoplasms/pathology , Retrospective Studies , Neoplasm Staging , Lymphatic Metastasis , Head and Neck Neoplasms/surgery , Head and Neck Neoplasms/pathology
2.
J Mycol Med ; 23(3): 179-84, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23856448

ABSTRACT

Mucormycosis is a rare, invasive and fatal disease that occurs mainly in diabetes mellitus patients with uncontrolled blood glucose levels or in immunocompromised patients. The mortality rate of this disease is as high as 25 to 80%, despite aggressive surgical treatment and antifungal therapy. This high mortality requires alternative treatment approaches. The accepted treatment modality of invasive mucormycosis are amphotericin B lipid formulations. Although echinocandins generally show no activity against Mucorales, it was shown that Rhizopus oryzae expressed the target enzyme for echinocandins, 1,3-beta-glucan synthase. Additionally, there are some experimental studies in a diabetic mouse model and case reports regarding the effects of caspofungin. In this report, we present a rhinocerebral mucormycosis case treated with liposomal amphotericin B and caspofungin. There was regression of the patient's clinical and radiological condition with the addition of caspofungin, but she died due to discontinuation of her treatment and reasons other than mucormycosis.


Subject(s)
Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Echinocandins/administration & dosage , Mucormycosis/drug therapy , Adult , Caspofungin , Diabetes Complications/drug therapy , Drug Therapy, Combination , Female , Humans , Immunocompromised Host , Lipopeptides
3.
Clin Transl Oncol ; 13(11): 826-30, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22082649

ABSTRACT

INTRODUCTION The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour. AIM We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC. MATERIAL AND METHOD Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis. RESULTS A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression- free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05). CONCLUSION This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.


Subject(s)
Carcinoma, Non-Small-Cell Lung/pathology , DNA-Binding Proteins/metabolism , Endonucleases/metabolism , Lung Neoplasms/pathology , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Chemotherapy, Adjuvant/methods , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Disease-Free Survival , Female , Humans , Immunohistochemistry , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Male , Middle Aged , Prognosis
4.
Clin. transl. oncol. (Print) ; 13(11): 826-830, nov. 2011. tab, ilus
Article in English | IBECS | ID: ibc-125945

ABSTRACT

INTRODUCTION The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour. AIM We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC. MATERIAL AND METHOD Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis. RESULTS A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression- free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05). CONCLUSION This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Carcinoma, Non-Small-Cell Lung/pathology , Endonucleases/metabolism , Lung Neoplasms/pathology , DNA-Binding Proteins/metabolism , Carcinoma, Non-Small-Cell Lung/drug therapy , Disease-Free Survival , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/metabolism , Chemotherapy, Adjuvant/methods , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Immunohistochemistry/methods , Immunohistochemistry , Lung Neoplasms/metabolism , Prognosis
5.
Minerva Endocrinol ; 36(2): 123-8, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21519321

ABSTRACT

AIM: The aim of this study was to determine the relationship between biochemical parameters, parathyroid adenoma volume, and bone mineral density with respect to intact parathyroid hormone (iPTH) levels in patients with primary hyperparathyroidism. METHODS: Data were collected retrospectively from patients with primary hyperparathyroidism who were diagnosed and followed in our clinic between 2005 and 2008. Forty-eight (female/male=42/6) patients with a mean age of 52.8±13.1 years were enrolled into the study. RESULTS: Bone pain was the most common presenting feature, seen in 41.7% of patients, while 29.1% of patients were asymptomatic. The mean serum calcium and iPTH concentrations were 2.9±0.6 mmol/L and 657.1±682 ng/L, respectively. The mean total Z/T scores of dual-energy X-ray absorptiometry (DEXA) scan at the femur and lumbar spine were -0.4±1.6/-1.0±1.7 and -1.4±1.6/-2.2±1.5, respectively. Preoperative iPTH levels were correlated with serum phosphate (r=-0.412, P=0.005), alkaline phosphatase (r=0.698, P=0.0001), and femur (r=-0.402, P=0.020) and lumbar spine total Z scores (r=-0.441, P=0.013), whereas parathyroid adenoma volume was correlated with iPTH (r=0.367, P=0.036) and alkaline phosphatase (r=0.570, P=0.001). There was no correlation between iPTH, serum calcium levels and total T scores at the femur and lumbar spine. After excluding patients with 25-OHD insufficiency, there was still no correlation between serum iPTH and calcium levels. Parathyroid adenoma volume, serum iPTH and calcium levels were also not different between patients with and without 25-OHD insufficiency. CONCLUSION: These results suggest that serum iPTH level may be useful in predicting parathyroid adenoma volume and it is also well correlated with femur and lumbar spine Z scores.


Subject(s)
Bone Density/physiology , Calcium/blood , Parathyroid Hormone/blood , Parathyroid Neoplasms/blood , Parathyroid Neoplasms/pathology , Absorptiometry, Photon , Adult , Aged , Female , Humans , Male , Middle Aged , Pain/etiology , Retrospective Studies , Young Adult
6.
J Int Med Res ; 38(6): 2146-52, 2010.
Article in English | MEDLINE | ID: mdl-21227020

ABSTRACT

Primary candidiasis in the laryngeal mucosa is rare but has many predisposing factors, in particular immune insufficiency and long-term antibiotic use. This study involved a reassessment of 530 laryngeal biopsy specimens originally examined between 2004 and 2009, from which 11 cases of hyperplastic laryngeal candidiasis were identified according to their clinical and histopathological features. Among possible predisposing factors, immune insufficiency was identified in three patients, there was long-term antibiotic use in two cases, use of inhaled corticosteroids in four cases, smoking in eight cases and reflux symptoms in four cases. Dysplasia as well as hyperplasia was seen in two cases. Endolaryngeal lesion excision was performed in eight cases and biopsy leading to radical surgery was done in three. In clinical follow-up no lesions were observed in nine cases while two had new leukoplakic lesions.


Subject(s)
Candidiasis/diagnosis , Laryngeal Mucosa/microbiology , Laryngeal Neoplasms/diagnosis , Adult , Candida/cytology , Candidiasis/microbiology , Diagnosis, Differential , Female , Humans , Hyphae/cytology , Laryngeal Mucosa/pathology , Male , Middle Aged
7.
JBR-BTR ; 90(3): 170-1, 2007.
Article in English | MEDLINE | ID: mdl-17696083

ABSTRACT

In this report a case with eosinophilic mastitis is described. The non specific radiologic findings of eosinophilic mastitis are illustrated. Diagnosis was established by histopathological exam of needle biopsy material. Knowledge of this rare entity may be helpful in diagnosis and clinical management.


Subject(s)
Eosinophilia/diagnosis , Mastitis/diagnosis , Biopsy, Needle , Female , Humans , Mammography , Middle Aged , Ultrasonography, Interventional , Ultrasonography, Mammary
8.
Int J Gynaecol Obstet ; 95(1): 35-9, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16919631

ABSTRACT

OBJECTIVE: To examine the relationships between the expression of protein Nm23 and surgical stage, histologic grade, histopathologic findings, and survival in women with endometrial carcinoma. METHODS: 19 patients with lymph node involvement were matched with 24 patients without lymph node involvement and the best paraffin-embedded blocks were selected for Nm23 immunohistochemical staining. The slides were evaluated semiquantitatively according to their degree of cytoplasmic staining. Statistical analysis was performed to determine whether there was a relationship between Nm23 expression and surgical stage, histologic grade, depth of myometrial invasion, lymph node metastasis, and/or lymphovascular space involvement. Survival analysis was also performed. RESULTS: Slides from 15 patients (79%) with lymph node involvement and 22 patients (88%) without lymph node involvement were found to be positive for Nm23 (P=0.01). No significant relations were observed between Nm23 expression and surgical stage, histologic grade, depth of myometrial invasion, or lymphovascular space involvement. Nm23 expression was found to be significantly related to lower rates of lymph node metastasis and longer survival (P=0.02). CONCLUSION: Elevated Nm23 expression is related to lower rates of lymph node metastasis and longer survival.


Subject(s)
Biomarkers, Tumor/metabolism , Endometrial Neoplasms/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Nucleoside-Diphosphate Kinase/metabolism , Endometrial Neoplasms/mortality , Endometrial Neoplasms/pathology , Female , Humans , Lymphatic Metastasis , Middle Aged , NM23 Nucleoside Diphosphate Kinases , Neoplasm Staging , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...